Search results for "Platelet"

showing 10 items of 786 documents

Plerixafor is effective and safe for stem cell mobilization in heavily pretreated germ cell tumor patients.

2010

Up to 10% of germ cell tumor patients require salvage high-dose chemotherapy with stem cell support, achieving cure rates in the range of 10-60%. Stem cell mobilization may be difficult in these patients because of multiple lines of treatment known to seriously hamper stem cell recovery. Plerixafor significantly enhances the success of the CD34+ cell harvest, even in cases where prior mobilization attempts have failed. Six germ cell tumor patients provided informed consent and were included in the compassionate use program. All patients were heavily pretreated, with a median of 3.5 prior lines of therapy. All failed prior mobilization with G-CSF in combination with chemotherapy. Five patien…

OncologyAdultCompassionate Use TrialsMalemedicine.medical_specialtyBenzylaminesPlatelet Engraftmentmedicine.medical_treatmentCD34Hematopoietic stem cell transplantationCyclamsYoung AdultTesticular NeoplasmsHeterocyclic CompoundsInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansUltrasonographyTransplantationChemotherapyMobilizationbusiness.industryPlerixaforHematopoietic Stem Cell TransplantationHematologyMiddle AgedNeoplasms Germ Cell and EmbryonalCombined Modality TherapyHematopoietic Stem Cell MobilizationSurgerySeminomamedicine.anatomical_structureStem cellbusinessGerm cellmedicine.drugBone marrow transplantation
researchProduct

A phase I/II multicentric trial of gemcitabine and epirubicin in patients with advanced pancreatic carcinoma

2006

Potential synergistic interaction between gemcitabine (GEM) and epirubicin (EPI) in pancreatic cancer have been described previously. The maximum-tolerated dose in this trial was GEM 1000 mg m(-2) and EPI 45 mg m(-2). Median time to progression was 5.1 months and median survival time 7.4 months. This combination appears well tolerated and shows promising clinical activity.

OncologyAdultMaleCancer Researchmedicine.medical_specialtyPancreatic diseaseendocrine system diseasesmedicine.drug_classmedicine.medical_treatmentpancreatic cancerAntineoplastic AgentschemotherapyAntimetaboliteDeoxycytidinechemistry.chemical_compoundHemoglobinsLeukocyte CountInternal medicinePancreatic cancerClinical StudiesmedicineHumansIn patientAgedNeoplasm StagingChemotherapyDose-Response Relationship Drugbusiness.industryPlatelet CountgemcitabineMiddle Agedmedicine.diseaseepirubicinGemcitabineSurgeryPancreatic NeoplasmsOncologychemistryDeoxycytidineFemalebusinessEpirubicinmedicine.drugBritish Journal of Cancer
researchProduct

Thrombin generation - a potentially useful biomarker of thrombotic risk in Philadelphia-negative myeloproliferative neoplasms.

2017

The diagnosis of essential thrombocythemia and polycythemia vera is often made during a thrombotic event which can be serious. Philadelphia-negative chronic myeloproliferative neoplasia patients have an increased thrombotic risk. This is assessed using various scoring systems but these are far from ideal and individual risk. The currend trend to personalised medicine requires finding the most useful thrombotic risk biomarker in these patients. Routine tests for coagulation do not take account of both pro- and anti-coagulant factors which is why these tests are not useful in patients with Philadelphia-negative myeloproliferative neoplasms. Thrombin generation reflects more accurately the bal…

OncologyBlood PlateletsPathologymedicine.medical_specialtylcsh:Medicinemyeloproliferative neoplasmsGeneral Biochemistry Genetics and Molecular BiologyLeukemia Myeloid Chronic Atypical BCR-ABL NegativeDiagnosis Differential03 medical and health sciences0302 clinical medicinePolycythemia verapolycythemia veraCell-Derived MicroparticlesRisk Factorshemic and lymphatic diseasesInternal medicinemedicineBiomarkers TumorHumansThrombophiliaPlateletjak2 v617fMyeloproliferative neoplasmessential thrombocythemiaEssential thrombocythemiabusiness.industrylcsh:RThrombinThrombosispersonalized medicineJanus Kinase 2medicine.diseaseThrombosisCoagulationthrombin generation030220 oncology & carcinogenesisplateletsBiomarker (medicine)Personalized medicinebusinessthrombotic risk030215 immunologyBiomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia
researchProduct

Systemic Inflammatory Markers and Oncologic Outcomes in Patients with High-risk Non-muscle-invasive Urothelial Bladder Cancer

2018

Background: Serum levels of neutrophils, platelets, and lymphocytes have been recognized as factors related to poor prognosis for many solid tumors, including bladder cancer (BC). Objective: To evaluate the prognostic role of the combination of the neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio (PLR), and lymphocyte/monocyte ratio (LMR) in patients with high-risk non–muscle-invasive urothelial BC (NIMBC). Design, setting, and participants: A total of 1151 NMIBC patients who underwent first transurethral resection of the bladder tumor (TURBT) at 13 academic institutions between January 1, 2002 and December 31, 2012 were included in this analysis. The median follow-up was 48 mo.…

OncologyMaleBladder cancer; Lymphocyte/monocyte ratio; Neutrophil/lymphocyte ratio; Platelet/lymphocyte ratio; Prognosis; Aged; Biomarkers Tumor; Blood Platelets; Carcinoma Transitional Cell; Cystectomy; Disease Progression; Female; Follow-Up Studies; Humans; Inflammation; Lymphocyte Count; Lymphocytes; Male; Monocytes; Neutrophils; Prognosis; Risk Factors; Urinary Bladder NeoplasmsNeutrophilsmedicine.medical_treatmentLymphocyte:Medicina Básica [Ciências Médicas]Prognosis.030232 urology & nephrologyMonocyteMonocytesSettore MED/24 - Urologia0302 clinical medicineRisk FactorsLymphocytesStage (cooking)Framingham Risk ScoreTumorNeutrophilBladder cancerPrognosis3. Good healthmedicine.anatomical_structureOncology030220 oncology & carcinogenesisNeutrophil/lymphocyte ratioCiências Médicas::Medicina BásicaDisease ProgressionLymphocyteFemalemedicine.symptomHumanBlood Plateletsmedicine.medical_specialtyPlatelet/lymphocyte ratioPrognosiUrologyInflammationCystectomyFollow-Up StudieCystectomy03 medical and health sciencesInternal medicinemedicineBiomarkers TumorHumansRadiology Nuclear Medicine and imagingLymphocyte CountAgedInflammationCarcinoma Transitional CellBladder cancerScience & Technologybusiness.industryProportional hazards modelRisk FactorCarcinomaLymphocyte/monocyte ratioImmunotherapymedicine.diseaseUrinary Bladder NeoplasmsBlood PlateletSurgeryTransitional CellbusinessBiomarkersFollow-Up Studies
researchProduct

Response to lenalidomide in myelodysplastic syndromes with del(5q): influence of cytogenetics and mutations.

2012

Summary Lenalidomide is an effective drug in low-risk myelodysplastic syndromes (MDS) with isolated del(5q), although not all patients respond. Studies have suggested a role for TP53 mutations and karyotype complexity in disease progression and outcome. In order to assess the impact of complex karyotypes on treatment response and disease progression in 52 lenalidomide-treated patients with del(5q) MDS, conventional G-banding cytogenetics (CC), single nucleotide polymorphism array (SNP-A), and genomic sequencing methods were used. SNP-A analysis (with control sample, lymphocytes CD3+, in 30 cases) revealed 5q losses in all cases. Other recurrent abnormalities were infrequent and were not ass…

OncologyMalemedicine.medical_specialtyMultivariate analysisCD3Single Nucleotide Polymorphism ArrayBiologyPolymorphism Single NucleotideInternal medicinemedicineHumansImmunologic FactorsPlateletLenalidomideIn Situ Hybridization FluorescenceLenalidomideAgedAged 80 and overMyelodysplastic syndromesCytogeneticsKaryotypeHematologyMiddle Agedmedicine.diseaseChromosome BandingThalidomideTreatment OutcomeMyelodysplastic SyndromesImmunologyMutationbiology.proteinDisease ProgressionChromosomes Human Pair 5FemaleChromosome Deletionmedicine.drugBritish journal of haematology
researchProduct

Clinical Applications, Pitfalls, and Uncertainties of Thrombin Generation in the Presence of Platelets

2019

Platelet-dependent thrombin generation is a helpful tool to assess ex vivo the interaction between platelets and plasma coagulation factors in the initiation, amplification, and inhibition of thrombin generation (TG). This review article discusses the most relevant available data on the clinical applications of fluorogenic TG, the most widely used TG assay, performed in the presence of platelets, i.e., in platelet-rich plasma. With respect to prothrombotic states, arterial hypertension and obesity were the most prominent cardiovascular conditions linked to increased platelet-dependent TG. In addition, platelet-associated hypercoagulability, assessed by the TG assay, has been shown in indivi…

Oncologycardiovascular risk factorsmedicine.medical_specialtyBLEEDING PHENOTYPElcsh:MedicineReview030204 cardiovascular system & hematologyHYPERCOAGULABILITYACTIVATION03 medical and health sciences0302 clinical medicineInternal medicinehemophiliamedicineVon Willebrand diseasePlateletSEVERE HEMOPHILIA-AthrombosisVENOUS THROMBOEMBOLISMRICH PLASMAbiologybusiness.industryCALIBRATED AUTOMATED THROMBOGRAMlcsh:RRECOMBINANT FACTOR VIIAGeneral Medicinemedicine.diseasebleedingThrombosisFACTOR-V DEFICIENCYcardiovascular diseasesBleeding diathesisCoagulationRecombinant factor VIIathrombin generationOBESITYplateletsbiology.proteinBiomarker (medicine)businessvon Willebrand diseaseEx vivo030215 immunologyJournal of Clinical Medicine
researchProduct


 Consistency and Proportionality in Policy Decision-Making in Blood Safety: the Case for an All-Apheresis Platelet Supply in Germany

2013

SUMMARY Recently, German investigators presented the first mathematical model finding a significant increase in the risk of HIV, HCV, and HBV transmission when pools of 4 whole-blood-derived buffy-coat platelets, rather than 1 singledonor (apheresis) component, are used to provide one platelet dose. Based, in both cases, on mathematical models employing the incidence/window-period method, the relative risk of transmission from pooled versus apheresis platelets (2.2 or 2.75 for HIV, 2.7 or 3.375 for HCV, and 3.2 or 4.0 for HBV, with pools of 4 or 5 concentrates, respectively) is similar to the difference in risk before (versus after) introduction of HIV-1 and HCV RNA screening. The absolute …

Oncologymedicine.medical_specialtybusiness.industryHuman immunodeficiency virus (HIV)Viral transmissionvirus diseasesPathogen reductionmedicine.disease_causeGeneral Biochemistry Genetics and Molecular BiologyPolicy decisionInternal medicineRelative riskImmunologymedicineBlood safetyPlateletbusinessModel findingClinical Laboratory
researchProduct

Baseline absolute neutrophil count (ANC), derived neutrophil-to-lymphocyte ratio (dNLR) and platelet-to-lymphocyte ratio (PLR) and outcome in non sma…

2017

Nivolumab (N) is a novel therapeutic option in NSCLC, with a significant survival gain compared with Docetaxel (D). However, predictive biomarkers are lacking and no strategies have been adopted to date for optimal patients (pts) selection. The presence of systemic inflammation has been correlated with poor outcome in many cancer types. We aimed to evaluate whether there is a correlation between some indicators of inflammation and response in pts treated with N or D.

Oncologymedicine.medical_specialtybusiness.industryLymphocytenon-small cell lung cancer (NSCLC)Hematology030204 cardiovascular system & hematologyNSCLCmedicine.diseasePreliminary analysis03 medical and health sciences0302 clinical medicinemedicine.anatomical_structureOncologyDocetaxel030220 oncology & carcinogenesisInternal medicinemedicineAbsolute neutrophil countPlateletNeutrophil to lymphocyte ratioNivolumabbusinessmedicine.drugAnnals of Oncology
researchProduct

A retrospective analysis of immunohistochemical determined IRF4 (interferon regulating factor 4) expression in a consecutive cohort of 114 ovarian ca…

2018

Oncologymedicine.medical_specialtybusiness.industrymedicine.diseaseInterferonInternal medicineCohortRetrospective analysisMedicineImmunohistochemistrybusinessOvarian cancerPlatelet factor 4IRF4medicine.drugGeburtshilfe und Frauenheilkunde
researchProduct

Secondary Stroke Prevention in Polish Adults: Results from the LIPIDOGRAM2015 Study

2021

Background: The purpose of the study was to evaluate secondary stroke prevention in Poland and its association with sociodemographic factors, place of residence, and concomitant cardiovascular risk factors. Material and methods: From all patients in LIPIDOGRAM2015 Study (n = 13,724), 268 subjects had a history of ischaemic stroke and were included. Results: 165 subjects (61.6%) used at least one preventive medication. Oral antiplatelet and anticoagulation agents were used by 116 (43.3%) and 70 (26.1%) patients, respectively. Only 157 (58.6%) participants used lipid-lowering drugs, and 205 (76.5%) were treated with antihypertensive drugs. Coronary heart disease (CHD) and dyslipidaemia were a…

Oral anticoagulant drugsmedicine.medical_specialtyRMArticleLifestyle modificationOral antiplatelet drugsInternal medicineIschaemic strokemedicineMyocardial infarctioncardiovascular diseasesSecondary stroke preventionStrokePrimary health careoral anticoagulant drugssecondary stroke preventionbusiness.industryRAtrial fibrillationoral antiplatelet drugsGeneral Medicinemedicine.diseaseR1Coronary heart diseaseprimary health careStroke preventionConcomitantMedicinebusiness
researchProduct